Zevra Therapeutics Inc (ZVRA)
4.82
-0.21
(-4.18%)
USD |
NASDAQ |
May 10, 16:00
4.835
+0.02
(+0.31%)
After-Hours: 20:00
Zevra Therapeutics Profit Margin (Quarterly): -114.6% for Dec. 31, 2023
Profit Margin (Quarterly) Chart
Historical Profit Margin (Quarterly) Data
| Date | Value |
|---|---|
| December 31, 2023 | -114.6% |
| September 30, 2023 | -485.1% |
| June 30, 2023 | -60.02% |
| March 31, 2023 | -408.7% |
| December 31, 2022 | |
| September 30, 2022 | -230.2% |
| June 30, 2022 | -1.85K% |
| March 31, 2022 | -47.01% |
| December 31, 2021 | -104.7% |
| Date | Value |
|---|---|
| September 30, 2021 | -89.52% |
| June 30, 2021 | 51.75% |
| March 31, 2021 | -84.97% |
| December 31, 2020 | -205.2% |
| September 30, 2020 | -156.3% |
| June 30, 2020 | 12.43% |
| March 31, 2020 | -275.4% |
| December 31, 2019 | -438.7% |
| September 30, 2019 | 26.72% |
Profit Margin Definition
Profit Margin is calculated using Net Income/Revenue. This metric measures the overall efficiency of a company in being able to turn revenue into profit. An analyst looking at profit margin might look for a higher profit margin relative to other comparable companies as well as a profit margin that is growing.
Profit Margin (Quarterly) Range, Past 5 Years
-1.85K%
Minimum
Jun 2022
51.75%
Maximum
Jun 2021
-262.3%
Average
-114.6%
Median
Dec 2023
Profit Margin (Quarterly) Benchmarks
| OptiNose Inc | -50.17% |
| Perspective Therapeutics Inc | -- |
| Dare Bioscience Inc | -279.8% |
| Kodiak Sciences Inc | -- |
| INmune Bio Inc | -30.03K% |
Profit Margin (Quarterly) Related Metrics
| Return on Equity | -66.86% |
| Return on Assets | -36.05% |
| Return on Invested Capital | -49.05% |
| Gross Profit Margin (Quarterly) | 84.88% |
| Operating Margin (Quarterly) | -111.0% |
| Return on Net Operating Assets | -125.9% |